In an article written for Pharmaphorum, Paul Ranson discusses international reliance, a mechanism whereby certain medical devices could access the UK market more quickly if they have already been approved by a comparable regulator, rather than undergoing a further full review for UK purposes only.
“In his March 2023 budget, the then UK Chancellor, Jeremy Hunt, accordingly announced that from 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) will adopt a new regulatory model, allowing for “near automatic sign-off for medicines and technologies already approved by trusted regulators in other parts of the world,”” explains Ranson.